Summit Therapeutics (SMMT) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.

Which has more risk & volatility, TAK or SMMT?

Takeda Pharmaceutical has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500.

Is TAK or SMMT more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 9.39% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Summit Therapeutics	N/A	-85.42%	-52.66%

Which has stronger earnings & valuation, TAK or SMMT?

Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.54
Summit Therapeutics	$700K	21,803.71	-$614.93M	-$0.31	-66.74

Does the MarketBeat Community prefer TAK or SMMT?

Summit Therapeutics received 207 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.48% of users gave Summit Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Summit Therapeutics	Outperform Votes 307 58.48%	Underperform Votes 218 41.52%

Do analysts rate TAK or SMMT?

Summit Therapeutics has a consensus target price of $34.11, indicating a potential upside of 64.87%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Summit Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Do institutionals & insiders have more ownership in TAK or SMMT?

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media favor TAK or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Summit Therapeutics and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.74 beat Summit Therapeutics' score of 0.70 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Takeda Pharmaceutical beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks.